计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B125646-1mg |
1mg |
现货 ![]() |
| |
| B125646-5mg |
5mg |
现货 ![]() |
| |
| B125646-25mg |
25mg |
现货 ![]() |
|
| 英文别名 | Butanediamide, N(sup 4)-hydroxy-N(sup 1)-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))- | batimastatum | (2R,3S)-N~1~-[(1S)-1-benzyl-2-(methylamino)-2-oxoethyl]-N~4~-hydroxy-2-(2-methylpr |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Batimastat |
| 生化机理 | 巴替马司他是一种强效、广谱的基质金属蛋白酶(MMP)抑制剂。巴替马司他是羟酰胺类基质金属蛋白酶(MMP)抑制剂。它能抑制肺部肿瘤的生长和扩散、乳腺癌的再生以及小鼠模型中人类结肠肿瘤的生长和扩散。巴替马司他可减少 MMP 介导的血管功能障碍和血管壁损伤,提高牙科粘合剂的密封能力和粘合强度。体内抗癌活性 . |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | MMP1 抑制剂;MMP13 抑制剂;MMP3 抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Batimastat 是一种有效的广谱 MMP 抑制剂,作用于 MMP-1,MMP-2,MMP-9,MMP-7 和 MMP-3,IC50 分别为 3,4,4,6 和 20 nM。Batimastat was used to study the role of MMP in proteolytic release of EGF in human follicular thyroid carcinoma cell line FTC-133. Batimastat is a potent broad spectrum MMP inhibitor with IC50 of 3, 4, 4, 6, and 20 nM for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3, respectively. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488195427 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide |
| INCHI | 1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1 |
| InChi Key | XFILPEOLDIKJHX-QYZOEREBSA-N |
| Smiles | CC(C)CC(C(CSC1=CC=CS1)C(=O)NO)C(=O)NC(CC2=CC=CC=C2)C(=O)NC |
| Isomeric SMILES | CC(C)C[C@H]([C@H](CSC1=CC=CS1)C(=O)NO)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC |
| 分子量 | 477.64 |
| Reaxy-Rn | 24715439 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24715439&ln= |
| 溶解性 | DMSO 96 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 分子量 | 477.600 g/mol |
| XLogP3 | 3.500 |
| 氢键供体数Hydrogen Bond Donor Count | 4 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 12 |
| 精确质量Exact Mass | 477.176 Da |
| 单同位素质量Monoisotopic Mass | 477.176 Da |
| 拓扑极表面积Topological Polar Surface Area | 161.000 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 614.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 3 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | Warning |
| WGK Germany | 3 |
| 1. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A et al.. (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.. Invest New Drugs, 14 (2): (193-202). [PMID:8913840] |
| 2. Parsons SL, Watson SA, Steele RJ. (1997) Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.. Eur J Surg Oncol, 23 (6): (526-31). [PMID:9484924] |
| 3. Beattie GJ, Smyth JF. (1998) Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.. Clin Cancer Res, 4 (8): (1899-902). [PMID:9717817] |
| 4. Oda SK et al.. (2020) A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.. J Exp Med, 217 (12): [PMID:32860705] |
| 5. Paschkowsky S et al.. (2016) Alternative Processing of the Amyloid Precursor Protein Family by Rhomboid Protease RHBDL4.. J Biol Chem, 291 (42): (21903-21912). [PMID:27563067] |
| 6. McColl R et al.. (2016) Analysis and quantification of in vitro myoblast fusion using the LADD Multiple Stain.. Biotechniques, 61 (6): (323-326). [PMID:27938324] |
| 7. Cremasco V et al.. (2014) B cell homeostasis and follicle confines are governed by fibroblastic reticular cells.. Nat Immunol, 15 (10): (973-81). [PMID:25151489] |
| 8. Beltramo E et al.. (2014) Extracellular vesicles derived from mesenchymal stem cells induce features of diabetic retinopathy in vitro.. Acta Diabetol, 51 (6): (1055-64). [PMID:25374383] |
| 9. Keppie SJ et al.. (2021) Matrix-Bound Growth Factors are Released upon Cartilage Compression by an Aggrecan-Dependent Sodium Flux that is Lost in Osteoarthritis.. Function (Oxf), 2 (5): (zqab037). [PMID:34423304] |
| 10. Ambite I et al.. (2016) Molecular Basis of Acute Cystitis Reveals Susceptibility Genes and Immunotherapeutic Targets.. PLoS Pathog, 12 (10): (e1005848). [PMID:27732661] |
| 11. Zhao Qu, Yushan Lin, Daniel Kam-Wah Mok, Qingya Bian, William Chi-Shing Tai, Sibao Chen. (2020) Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/mTOR and STAT3 Signaling Pathways. International Journal of Medical Sciences, 17 (11): ( 1482–1490). [PMID:32669950] [10.7150/ijms.46925] |